These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27166257)

  • 21. Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma.
    Zhang Y; Zhang B; Li Y; Dai Y; Li J; Li D; Xia Z; Zhang J; Liu P; Chen M; Jiao B; Ren R
    Front Med; 2022 Oct; 16(5):784-798. PubMed ID: 35997986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
    Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
    J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uveal melanoma-associated mutations in PLCβ4 are constitutively activating and promote melanocyte proliferation and tumorigenesis.
    Phan HTN; Kim NH; Wei W; Tall GG; Smrcka AV
    Sci Signal; 2021 Dec; 14(713):eabj4243. PubMed ID: 34905385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.
    Feng X; Degese MS; Iglesias-Bartolome R; Vaque JP; Molinolo AA; Rodrigues M; Zaidi MR; Ksander BR; Merlino G; Sodhi A; Chen Q; Gutkind JS
    Cancer Cell; 2014 Jun; 25(6):831-45. PubMed ID: 24882515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in GNA11 in uveal melanoma.
    Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
    N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
    Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
    Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
    Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS
    Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
    Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
    Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Status of RASSF1A in uveal melanocytes and melanoma cells.
    Calipel A; Abonnet V; Nicole O; Mascarelli F; Coupland SE; Damato B; Mouriaux F
    Mol Cancer Res; 2011 Sep; 9(9):1187-98. PubMed ID: 21788308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells.
    Calipel A; Mouriaux F; Glotin AL; Malecaze F; Faussat AM; Mascarelli F
    J Biol Chem; 2006 Apr; 281(14):9238-50. PubMed ID: 16452469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mass Spectrometry-Based Profiling of Histone Post-Translational Modifications in Uveal Melanoma Tissues, Human Melanocytes, and Uveal Melanoma Cell Lines - A Pilot Study.
    Herwig-Carl MC; Sharma A; Tischler V; Pelusi N; Loeffler KU; Holz FG; Zeschnigk M; Landreville S; Auw-Haedrich C; Noberini R; Bonaldi T
    Invest Ophthalmol Vis Sci; 2024 Feb; 65(2):27. PubMed ID: 38349785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.
    Weber A; Hengge UR; Urbanik D; Markwart A; Mirmohammadsaegh A; Reichel MB; Wittekind C; Wiedemann P; Tannapfel A
    Lab Invest; 2003 Dec; 83(12):1771-6. PubMed ID: 14691295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
    Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
    Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
    Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.
    Moore AR; Ceraudo E; Sher JJ; Guan Y; Shoushtari AN; Chang MT; Zhang JQ; Walczak EG; Kazmi MA; Taylor BS; Huber T; Chi P; Sakmar TP; Chen Y
    Nat Genet; 2016 Jun; 48(6):675-80. PubMed ID: 27089179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What hope for the future? GNAQ and uveal melanoma.
    Sisley K; Doherty R; Cross NA
    Br J Ophthalmol; 2011 May; 95(5):620-3. PubMed ID: 21378004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
    Musi E; Ambrosini G; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRas-ERK signalling promotes the onset and maintenance of uveal melanoma through regulating JMJD6-mediated H2A.X phosphorylation at tyrosine 39.
    Li Y; Yu P; Zou Y; Cai W; Sun W; Han N
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4257-4265. PubMed ID: 31736361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.